Fred Middleton


Fred Middleton has over thirty years experience in the biotechnology and biomedical industries in both corporate management and as a new venture investor. Mr. Middleton joined Dr. McNeil in 1987 as a General Partner of Sanderling. Since 1987, Mr. Middleton has worked on venture capital investments and the corporate development of early-stage biomedical companies at Sanderling, serving as a founder, investor, management team member and director of many start-up ventures in Sanderling’s portfolio.

Over the last several years, he has played active management roles as Chairman, CEO or Director of a number of Sanderling portfolio companies, currently including Stereotaxis (NASDAQ: STXS), CardioNet (NASDAQ: BEAT), Novocell, Cylene, Endocyte, Altor and Actimis.

Mr. Middleton began his career as a consultant for McKinsey & Company’s San Francisco office from 1973 to 1975. He subsequently worked as a Vice President in planning and corporate development Chase Manhattan Bank in New York. In 1978, Mr. Middleton joined Bob Swanson and Herb Boyer, the founders of biotechnology pioneer Genentech, Inc., as the third member of original management team, where he served in various capacities, including Vice President of Finance, Administration, Corporate Development, Chief Financial Officer, and as President of Genentech Development Corporation. While at Genentech, Mr. Middleton successfully completed over $200 million in corporate partnering and institutional funding transactions, including the Company’s successful IPO in 1980.

After Genentech, Mr. Middleton founded Morgan Stanley Ventures in 1984, serving as Managing General Partner of an institutional fund raised to sponsor R&D funding arrangements at leading technology companies in the biomedical sciences and information technology fields.

Mr. Middleton earned his B.S. in chemistry from the Massachusetts Institute of Technology in 1971 and an M.B.A with distinction from Harvard Business School in 1973.